Medical devices, healthcare technology and the business of care
510(k) clearance · K260221

Elecsys EBV EBNA IgG

Roche Diagnostics · Decision date Oct 2, 2026

MEDTECHLEDGER EXPLANATIONK260221

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on 10/02/2026 for Elecsys EBV EBNA IgG, submitted by Roche Diagnostics of Indianapolis, Indiana, under 510(k) number K260221. The application was received 01/26/2026 and reviewed in the Microbiology panel and regulation medical specialty, with classification product code LSE and subsequent product codes LLM and MCD. The device classification name listed is Epstein-Barr Virus, Other, under regulation number 866.3235.

SESE in the 510(k) pathway denotes clearance to market, not premarket approval. The record describes a traditional review not conducted by a third party, and it lists no combination product and no authorized predetermined change control plan. The public record does not include the decision summary text, so the specific device components, comparison predicate, and performance evidence supporting the clearance remain unknown from this source.

The page also lists applicant contact Linda McCammack and correspondent contact Cynthia Aker, with a page last updated date of 10/26/2026. No clinical claims, indications, or analytical performance figures appear in the available material, and none should be inferred from the clearance alone.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Oct 2, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K260221
Regulatory pathway
510(k) premarket notification
Product code
LSE
Decision code
SESE
Decision date
Oct 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Epstein-Barr Virus, Other.

Product code
LSE
FDA device class
1

FDA decision timeline

  1. K260221 received

    Application receipt date recorded by FDA.

  2. K260221 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code LSE

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Diagnostics510(k) clearanceOct 2, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Diagnostics

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Indianapolis, IN

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records